PUNE, India, December 13, 2016 /PRNewswire/ --
The report "Clinical Trial Imaging Market by Product & Services (Software), Modality (CT, MRI, PET, Ultrasound, Echocardiography, X-Ray), End User (Pharmaceutical Companies, Biotechnology Companies, CROs, Medical Device Manufacturers) - Global Forecast to 2021" The global market is projected to reach USD 1069.7 Million by 2021 from USD 773.4 Million in 2016, at a CAGR of 6.7% from 2016 to 2021. The report provides a granular understanding of the clinical trials imaging market.
(Logo: http://photos.prnewswire.com/prnh/20160303/792302 )
Browse 77 market data Tables and 32 Figures spread through 123 Pages and in-depth TOC on "Clinical Trial Imaging Market"
http://www.marketsandmarkets.com/Market-Reports/clinical-trials-imaging-market-30446624.html
Early buyers will receive 10% customization on this report.
The report provides a detailed overview of major drivers, restraints, challenges, opportunities, current market trends and strategies impacting the global market along with estimates and forecast of revenue.
Major factors fueling market growth are the increasing number of contract research organizations, growth in the pharmaceutical and biotechnology industries, and increase in R&D spending are the key drivers for the growth of the clinical trial imaging market. On the other hand, the high implementation cost of imaging systems is restraining the growth of this market.
Inquiry before Buying @ http://www.marketsandmarkets.com/Enquiry_Before_Buying.asp?id=30446624
The clinical trial imaging market, on the basis of product and service, is segmented into service and software. Of these, the service segment is expected to account for the largest share as well as the highest CAGR of the clinical trial imaging market in 2016. The large share of this segment can primarily be attributed to high cost of the imaging equipment, which is leading to increased outsourcing of imaging clinical trial by pharmaceutical, biotechnology, and medical device manufacturers to service providers. On the basis of type, the services segment is further classified into operational imaging services, reader services, systems and technology support services, and design consulting services.
The operational imaging services segment is expected to account for the largest share of the global clinical trial imaging services market in 2016 as it constitutes the core services offered by imaging CROs for different imaging modalities. Furthermore, on the basis of modality, the clinical trial imaging market is broadly classified into CT, MRI, PET, ultrasound, ECHO, x-ray, and other modalities. In 2016, the CT segment is expected to account for the largest share of the global clinical trial imaging market. The large share of this segment is attributed to the high advantages of CT in screenings for cancer (tumors), injuries, and abnormalities inside the body. Similarly, in 2016, the PET segment is expected to grow at a highest CAGR in the clinical trial imaging market. The highest growth of this segment is primarily attributed to the high advantages of PET in providing information about the function and metabolism of the body's organs.
On the basis of end user, the clinical trial imaging market is categorized into pharmaceutical companies, biotechnology companies, medical device manufacturers, contract research organizations, academic and government research institutes, and other end users. Pharmaceutical companies are expected to account for the largest share of the global clinical trial imaging end user market in 2016. Increased R&D budgets of pharmaceutical companies is the primary growth driver for this end-user segment. However, medical device manufacturers are growing at a highest CAGR in the forecast period. Increased R&D spending by medical device manufacturers and the growing medical devices market are the primary growth drivers of the medical device manufacturer's end user segment.
Buy Report @ https://www.marketsandmarkets.com/Purchase/purchase_report1.asp?id=30446624
Geographically, the clinical trial imaging market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). North America is expected to command the largest share of the global clinical trial imaging market in 2016. This market is primarily driven by large R&D spending, growing number of pharmaceutical & biotechnology companies, and increasing number of CROs. Asia is expected to grow at the highest CAGR in the forecast period. The growth in the Asian clinical trial imaging market is driven by the growth in pharmaceutical & biotechnology industries and increase in R&D spending in the region.
The key players in the global clinical trial imaging market are BioClinica, Inc. (U.S.), Biomedical Systems (U.S.), Cardiovascular Imaging Technologies (U.S.), ICON Public Limited Company (Ireland), Intrinsic Imaging, LLC (U.S.), IXICO, PLC (U.K.), PAREXEL International Corporation (U.S.), Radiant Sage, LLC (U.S.), BioTelemetric, Inc. (U.S.), and WorldCare Clinical, LLC (U.S.).
Browse Related Reports:
Preclinical Imaging (In-VIVO) Market by Modality (Optical Imaging, PET, SPECT, CT, MRI, ultrasound, Photoacoustic Imaging, Magnetic Particle Imaging), Reagent (Optical Imaging Reagents, Contrast Agents, PET Tracers, SPECT Probes) - Global Forecast to 2021
http://www.marketsandmarkets.com/Market-Reports/pre-clinical-molecular-imaging-market-841.html
3D Imaging Market by Display Technology (Anaglyphy, Stereoscopy, Auto-stereoscopy), Imaging Solution (3D Modeling, 3D Scanning), Hardware (3D Display, 3D Sensor), Industry Vertical, & Region - Global Forecast to 2020
http://www.marketsandmarkets.com/Market-Reports/3d-imaging-market-998.html
About MarketsandMarkets
MarketsandMarkets is the largest market research firm worldwide in terms of annually published premium market research reports. Serving 1700 global fortune enterprises with more than 1200 premium studies in a year, M&M is catering to a multitude of clients across 8 different industrial verticals. We specialize in consulting assignments and business research across high growth markets, cutting edge technologies and newer applications. Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors.
M&M's flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. The new included chapters on Methodology and Benchmarking presented with high quality analytical infographics in our reports gives complete visibility of how the numbers have been arrived and defend the accuracy of the numbers.
We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository.
Subscribe Reports from Healthcare Domain @ http://www.marketsandmarkets.com/Knowledgestore.asp
Contact:
Mr. Rohan
MarketsandMarkets
701 Pike Street
Suite 2175, Seattle,
WA 98101, United States
Telephone No: 1-888-600-6441
Email: [email protected]
Visit MarketsandMarkets Blog @ http://mnmblog.org/market-research/healthcare/medical-devices
Connect with us on LinkedIn @ http://www.linkedin.com/company/marketsandmarkets
Share this article